Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma

29 Jun 2017

Abstract excerpt

BRAF and NRAS genetic analyses are time-consuming and can delay treatment choices in patients with metastatic melanomas presenting with acute deterioration. We compared the rapid, real-time, fully automated molecular diagnosis platform Idylla™ with next-generation sequencing (NGS) and immunohistochemistry for detection of BRAF and NRAS mutations in 36 patients with metastatic melanomas. The Idylla™...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to Cutaneous Melanoma Detection and Management
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28660280
DOI: 10.2340/00015555-2738

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in MelanomaPMID 28660280Read ↗

Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.Semantic proximity Read ↗

Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.Semantic proximity Read ↗

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.Semantic proximity Read ↗

Improving care of melanoma patients through efficient, integrated cellular-molecular pathology workflows using tissue samples with low tumour nuclear content.Semantic proximity Read ↗

The Current State of Molecular Testing in the BRAF-Mutated Melanoma LandscapeSemantic proximity Read ↗

Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies.Semantic proximity Read ↗

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicineSemantic proximity Read ↗

Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma.Semantic proximity Read ↗

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.Semantic proximity Read ↗

Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.Semantic proximity Read ↗

[Rapid Idylla™ mutational testing: Current and future theranostic applications].Semantic proximity Read ↗

Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.